SCHEMBL25456590

SCHEMBL25456590

CCCCCCCCOc1ccc(CCCC(=O)OC)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 1/20 0.56
S1PR4 O95977 2/20 0.55
S1PR1 P21453 2/20 0.55
S1PR3 Q99500 2/20 0.55
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MEN1 O00255 1/20 0.55
USP2 O75604 1/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP3A4 P08684 1/20 0.55
MAPK1 P28482 1/20 0.55
CASP1 P29466 1/20 0.55
KMT2A Q03164 1/20 0.55
SLCO1B3 Q9NPD5 1/20 0.55
SLCO1B1 Q9Y6L6 1/20 0.55
TP53 P04637 1/20 0.54
TSHR P16473 1/20 0.54
S1PR5 Q9H228 1/20 0.53
PLA2G4B P0C869 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1667448 1.00 PLA2G4A (0.56) PLA2G4AS1PR4S1PR1S1PR3LMNA
SCHEMBL25176144 0.94 PLA2G4A (0.53) PLA2G4AS1PR4S1PR1S1PR3LMNA
SCHEMBL6539026 0.93 LMNA (0.57) PLA2G4AS1PR4S1PR1S1PR3LMNA
SCHEMBL10334162 0.93 LMNA (0.57) PLA2G4AS1PR4S1PR1S1PR3LMNA
SCHEMBL25172916 0.93 LMNA (0.57) PLA2G4AS1PR4S1PR1S1PR3LMNA
SCHEMBL17349905 0.93 LMNA (0.57) PLA2G4AS1PR4S1PR1S1PR3LMNA
SCHEMBL22439030 0.93 LMNA (0.57) PLA2G4AS1PR4S1PR1S1PR3LMNA
Cyclopropane SCHEMBL11854090 0.92 PLA2G4A (0.55) PLA2G4AS1PR4S1PR1S1PR3LMNA
SCHEMBL14162907 0.88 ALDH1A1 (0.58) LMNASMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL7528179 0.88 LMNA (0.62) LMNASMN1; SMN2ALDH1A1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 US disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 PLA2G4A 15/4885S1PR4 12/4885S1PR1 32/4885
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE LPAR4, LPAR2, LPAR1 PLA2G4A 16/4885S1PR4 12/4885S1PR1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.